 |
AstraZeneca partners with M42 to advance breast cancer interventionM42, a first-of-its-kind tech-enabled global health powerhouse, has signed a groundbreaking agreement with AstraZeneca, a global leader in science-led biopharmaceuticals, to advance preventive healthcare and next-generation precision medicine. More… |
 |
AstraZeneca to move to Tecom Group’s Dubai Science ParkAstraZeneca has announced plans to construct sustainable offices at Dubai Science Park, a member of Tecom Group PJSC. Set to open in Q3 2023, the move is part of the biopharmaceutical giant’s global More… |
|
AstraZeneca to move to Tecom Group’s Dubai Science ParkAstraZeneca has announced plans to construct sustainable offices at Dubai Science Park, a member of Tecom Group PJSC. Set to open in Q3 2023, the move is part of the biopharmaceutical giant’s global More… |
 |
AstraZeneca signs landmark biotechnology deals with KSAAstraZeneca has signed two landmark agreements on innovation and R&D with Saudi Arabian entities that will support healthcare transformation in the kingdom. AstraZeneca and Ministry of National Guard More… |
 |
AstraZeneca tops the list in Best Places to Work in MideastAstraZeneca, the leading multinational pharmaceutical and biotechnology company, has topped the list of the Best Places to Work in the Middle East, followed by BSH and Roshn. The certification recognises More… |
|
AstraZeneca tops the list in Best Places to Work in MideastAstraZeneca, the leading multinational pharmaceutical and biotechnology company, has topped the list of the Best Places to Work in the Middle East, followed by BSH and Roshn. The certification recognises More… |
|
AstraZeneca tops the list in Best Places to Work in MideastAstraZeneca, the leading multinational pharmaceutical and biotechnology company, has topped the list of the Best Places to Work in the Middle East, followed by BSH and Roshn. The certification recognises More… |
 |
Japan approves AstraZeneca drug for Covid treatmentTop pharma group AstraZeneca said its Evusheld (tixagevimab and cilgavimab, formerly AZD7442), a long-acting antibody combination, has been approved in Japan for both prevention (pre-exposure prophylaxis) and treatment of symptomatic disease c More… |
 |
Evusheld retains neutralising activity against Omicron variantsAstraZeneca’s Evusheld (tixagevimab and cilgavimab, formerly AZD7442) retains neutralisation activity against the emerging Omicron BA.4 and BA.5 (BA.4/5) variants, says preclinical pseudovirus assay data from the University of Oxford.&nb More… |
 |
AstraZeneca launches global R&D Postdoctoral ChallengeAstraZeneca, a global, science-led biopharmaceutical company, has launched a global R&D Postdoctoral Challenge to help accelerate ideas to transform the treatment of some of the world’s most complex diseases. More… |
